Fennec Pharmaceuticals Inc. (FENC) Cash Flow Statement

The gap between FENC's $2.0M net income and $50K operating cash flow in 2026Q2 is primarily explained by a $3.4M working capital outflow, likely reflecting a receivables build on newly recognized commercial revenue that has not yet been collected. This pattern is consistent with a royalty-based model where revenue is recognized on delivery but cash follows collection cycles; investors should monitor whether the following quarter shows a corresponding receivable release, as the +$7.3M working capital inflow in 2025Q3 demonstrates that catch-up does occur. The low conversion ratio suggests reported profitability is not yet translating into durable cash generation, which is material for a company that posted net losses in seven of the last ten quarters.

With zero capex in every quarter reviewed, FENC's free cash flow tracks operating cash flow directly, revealing a capital-light royalty licensing model that does not require reinvestment in manufacturing or infrastructure. The shift from cumulative negative FCF in 2024-2025 to positive results in 2026 aligns with the revenue inflection observed in the income statement, but the sharp sequential deceleration from $2.4M to $50K indicates the cash trajectory is not yet self-sustaining. The absence of capex also implies that FENC's future cash flows depend on external milestone receipts and license extensions rather than internally generated pipeline economics.

The extreme volatility in FENC's working capital—swinging from +$7.3M in 2025Q3 to -$9.3M in 2025Q4 and -$3.4M in 2026Q2—suggests cash receipts are tied to milestone events rather than smooth quarterly royalty streams, which is common in licensing-driven biotech models. This pattern means reported operating cash flow in any single quarter is a poor indicator of underlying commercial performance; the 2025Q3 positive $1.5M OCF, for instance, reflected prior revenue collections rather than current-period operating strength. Investors should weight the cumulative trajectory rather than quarterly figures, and monitor whether working capital stabilizes as the commercial base matures.

The absence of dividends, meaningful buybacks, and acquisitions across the ten-quarter window—despite the $39.0M operating cash inflow in 2024Q1—suggests FENC management is conserving cash for ongoing operating losses and potential future licensing commitments rather than signaling shareholder-return confidence. This posture is not unusual for a commercial-stage biotech that has not yet demonstrated sustained positive cash flow, but it means investors have no valuation support from capital return mechanisms. Given the cumulative net loss of approximately $8.1M against $16.9M cumulative operating cash flow (a figure that includes the anomalous $39.0M milestone quarter), the balance sheet reserve may be more constrained than top-line momentum suggests.